AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Byline: Christopher Rowland
Apr. 18--For-profit dialysis chains in the United States give patients larger doses of the expensive antianemia drug Epogen compared to nonprofit clinics, according to a study to be published today in the Journal of the American Medical Association.
In many cases, the larger doses boost red blood cell levels beyond what is recommended by the Food and Drug Administration, the study said.
The article suggests the increased use of Epogen is the result of financial incentives built into the federal Medicare reimbursement rate for the drug, and volume discounts offered by its manufacturer, Amgen Inc., of Thousand Oaks, Calif.…